The importance of the expression profile of claudins in the molecular classification of breast cancer (BC) is currently under investigation. Claudins, together with cadherins, serve an important role in the epithelial-mesenchymal transition and influence the chemosensitivity of cancer cells. Adjuvant chemotherapy is administered following surgical resection in selected cases of BC. Previous neoadjuvant chemotherapy may change the molecular profile of a tumour and subsequently also its chemosensitivity. In the current study, the expression of claudin-1, -3 and -4, E- and N-cadherin and the standard BC biomarkers [oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and marker of proliferation Ki-67 (Ki-67)] in formalin-fixed, paraffin-embedded sections from 62 patients with invasive BC was analysed using immunohistochemistry prior to and following neoadjuvant chemotherapy. The results revealed increased expression of claudin-1 (P=0.03) and decreased expression of claudin-3 (P=0.005), PR (P<0.001) and Ki-67 (P=0.01) following the neoadjuvant therapy. No significant changes in the expression of ER, claudin-4 or E- and N-cadherin were observed following therapy. Furthermore, an association between the expression of claudin-1 and the standard BC markers (P<0.05) was identified. A high expression of claudin-1 was more frequently observed in the triple-negative BC cohort than in the cohort with positive ER, PR and/or HER2 before (P=0.04) and after chemotherapy (P=0.02). The expression of N-cadherin was associated with the expression of ER, PR, HER2 and tumour grade (P<0.05). A positive association between the expression of claudin-3 and E-cadherin (P=0.005) was observed. No association was found between the expression of E- and N-cadherin. In conclusion, significant changes in the expression of claudin-1 and -3 but not in the expression of claudin-4, E- and N-cadherin were observed in samples taken from patients with BC following chemotherapy. These findings indicate that claudins-1 and -3 serve a role in the response of BC to chemotherapy.

1st Faculty of Medicine Charles University 12108 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

Zobrazit více v PubMed

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. Fourth. IARC; Lyon: 2012. WHO classification of tumours of the breast.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. PubMed DOI

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. PubMed DOI PMC

Myal Y, Leygue E, Blanchard AA. Claudin 1 in breast tumorigenesis: Revelation of a possible novel ‘claudin high’ subset of breast cancers. J Biomed Biotechnol. 2010;2010:956897. doi: 10.1155/2010/956897. PubMed DOI PMC

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. doi: 10.1186/bcr2635. PubMed DOI PMC

Ellis IO, Carder P, Hales S, Lee A, Pinder S, Rakha E, Stephenson T. Pathology reporting of breast disease in surgical excision speciemens incorporating tha dataset for histological reporting of breast cancer. Royal College of Pathologists. 2016

Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, Tamura A, Igarashi M, Endo T, Takeuchi K, Tsukita S. Predicted expansion of the claudin multigene family. FEBS Lett. 2011;585:606–612. doi: 10.1016/j.febslet.2011.01.028. PubMed DOI

Kulka J, Tökés AM. Claudin expression in breast tumours. Hum Pathol. 2005;36:859–860. doi: 10.1016/j.humpath.2005.04.005. PubMed DOI

Ding L, Lu Z, Lu Q, Chen YH. The claudin family of proteins in human malignancy: A clinical perspective. Cancer Manag Res. 2013;5:367–375. PubMed PMC

Turksen K, Troy TC. Junctions gone bad: Claudins and loss of the barrier in cancer. Biochim Biophys Acta. 2011;1816:73–79. PubMed

Singh AB, Sharma A, Dhawan P. Claudin family of proteins and cancer: An overview. J Oncol. 2010;2010:541957. doi: 10.1155/2010/541957. PubMed DOI PMC

Kwon MJ. Emerging roles of claudins in human cancer. Int J Mol Sci. 2013;14:18148–18180. doi: 10.3390/ijms140918148. PubMed DOI PMC

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76. doi: 10.1186/gb-2007-8-5-r76. PubMed DOI PMC

Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150–1160. doi: 10.1002/cncr.11603. PubMed DOI

Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5–23. doi: 10.1016/j.molonc.2010.11.003. PubMed DOI PMC

Saeki R, Kondoh M, Kakutani H, Tsunoda S, Mochizuki Y, Hamakubo T, Tsutsumi Y, Horiguchi Y, Yagi K. A novel tumour-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol. 2009;76:918–926. doi: 10.1124/mol.109.058412. PubMed DOI

Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I, Lemm M, Piontek J, Blasig IE, Stein U, Schlag PM. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and −4-overexpressing tumors. Gene Ther. 2012;19:494–503. doi: 10.1038/gt.2011.136. PubMed DOI

Morin PJ. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res. 2005;65:9603–9606. doi: 10.1158/0008-5472.CAN-05-2782. PubMed DOI

Singh AB, Dhawan P. Claudins and cancer: Fall of the soldiers entrusted to protect the gate and keep the barrier intact. Semin Cell Dev Biol. 2015;42:58–65. doi: 10.1016/j.semcdb.2015.05.001. PubMed DOI

Osanai M, Takasawa A, Murata M, Sawada N. Claudins in cancer: Bench to bedside. Pflugers Arch. 2017;469:55–67. doi: 10.1007/s00424-016-1877-7. PubMed DOI

Lin X, Shang X, Manorek G, Howell SB. Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PLoS One. 2013;8:e67496. doi: 10.1371/journal.pone.0067496. PubMed DOI PMC

Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751. doi: 10.1038/onc.2010.215. PubMed DOI PMC

Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779–790. doi: 10.1083/jcb.148.4.779. PubMed DOI PMC

Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147:631–644. doi: 10.1083/jcb.147.3.631. PubMed DOI PMC

Rai H, Ahmed J. N-cadherin: A marker of epithelial to mesenchymal transition in tumour progression. Internet J Oncol. 2014;10:1–8.

Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y. Claudin 1 in breast cancer: New insights. J Clin Med. 2015;4:1960–1976. doi: 10.3390/jcm4121952. PubMed DOI PMC

Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198:281–293. doi: 10.1083/jcb.201202014. PubMed DOI PMC

Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–228. doi: 10.1097/00000421-199306000-00006. PubMed DOI

Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol. 2008;21:1320–1329. doi: 10.1038/modpathol.2008.116. PubMed DOI

Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E. Claudin expression in high-grade invasive ductal carcinoma of the breast: Correlation with the molecular subtype. Mod Pathol. 2013;26:485–495. doi: 10.1038/modpathol.2012.187. PubMed DOI PMC

Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, Levine M, Whelan T, Bane AL. Claudin-low breast cancer; Clinical & pathological characteristics. PLoS One. 2017;12:e0168669. doi: 10.1371/journal.pone.0168669. PubMed DOI PMC

Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J, Schmitt F. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast. 2012;21:354–360. doi: 10.1016/j.breast.2012.03.001. PubMed DOI

Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5:R217–R222. doi: 10.1186/bcr651. PubMed DOI PMC

Dewis R, Gribbin J. National Collaborating Centre for Cancer (UK); Cardiff, UK: 2009. Breast cancer: Diagnosis and treatment: An assessment of need. PubMed

Ordóñez NG. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am J Clin Pathol. 2013;139:611–619. doi: 10.1309/AJCP0B3YJBXWXJII. PubMed DOI

Szabó I, Kiss A, Schaff Z, Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol. 2009;24:1607–1615. PubMed

Worsley CM, Mayne ES, Veale RB. Clone war: The evolution of therapeutic resistance in cancer. Evol Med Public Health. 2016;2016:180–181. doi: 10.1093/emph/eow015. PubMed DOI PMC

Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep. 2016;6:36198. doi: 10.1038/srep36198. PubMed DOI PMC

Asogan AB, Hong GS, Arni Prabhakaran SK. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer. Singapore Med J. 2017;58:145–149. doi: 10.11622/smedj.2016062. PubMed DOI PMC

Dekker TJ, Smit VT, Hooijer GK, Van de Vijver MJ, Mesker WE, Tollenaar RA, Nortier JW, Kroep JR. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 2013;24:931–937. doi: 10.1093/annonc/mds599. PubMed DOI

You K, Park S, Ryu JM, Kim I, Lee SK, Yu J, Kim SW, Nam SJ, Lee JE. Comparison of core needle biopsy and surgical specimens in determining intrinsic biological subtypes of breast cancer with immunohistochemistry. J Breast Cancer. 2017;20:297–303. doi: 10.4048/jbc.2017.20.3.297. PubMed DOI PMC

Kinsella MD, Nassar A, Siddiqui MT, Cohen C. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience. Int J Clin Exp Pathol. 2012;5:530–536. PubMed PMC

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH. Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:858–862. (In Chinese) PubMed

van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37:422–430. PubMed

Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. J Surg Oncol. 2017;116:1021–1028. doi: 10.1002/jso.24762. PubMed DOI

Li P, Liu T, Wang Y, Shao S, Zhang W, Lv Y, Yi J, Wang Z. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. Clin Breast Cancer. 2013;13:53–60. doi: 10.1016/j.clbc.2012.09.011. PubMed DOI

Cabrera-Galeana P, Muñoz-Montaño W, Lara-Medina F, Alvarado-Miranda A, Pérez-Sánchez V, Villarreal-Garza C, Quintero RM, Porras-Reyes F, Bargallo-Rocha E, Del Carmen I, et al. Ki67 Changes identify worse outcomes in residual breast cancer tumors after neoadjuvant chemotherapy. Oncologist. 2018;23:670–678. doi: 10.1634/theoncologist.2017-0396. PubMed DOI PMC

Moazed V, Jafari E, Kalantari Khandani B, Nemati A, Roozdar A, Ben Razavi SA. Prognostic significance of reduction in Ki67 index after neoadjuvant chemotherapy in patients with breast cancer in kerman between 2009 And 2014. Iran J Pathol. 2018;13:71–77. doi: 10.30699/ijp.13.1.71. PubMed DOI PMC

Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. J BUON. 2013;18:366–371. PubMed

Lee HC, Ko H, Seol H, Noh DY, Han W, Kim TY, Im SA, Park IA. Expression of immunohistochemical markers before and after neoadjuvant chemotherapy in breast carcinoma, and their use as predictors of response. J Breast Cancer. 2013;16:395–403. doi: 10.4048/jbc.2013.16.4.395. PubMed DOI PMC

Zhou X, Zhang J, Yun H, Shi R, Wang Y, Wang W, Lagercrantz SB, Mu K. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: Tumor heterogeneity should be taken into consideration. Oncotarget. 2015;6:36894–36902. doi: 10.18632/oncotarget.5050. PubMed DOI PMC

Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2015;22:185–191. doi: 10.1007/s12282-013-0474-2. PubMed DOI

Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J. 2008;14:141–146. doi: 10.1111/j.1524-4741.2007.00544.x. PubMed DOI

Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update summary. J Oncol Pract. 2018;14:437–441. doi: 10.1200/JOP.18.00206. PubMed DOI

Davila E, Amazon K. The clinical importance of the heterogeneity of HER2 neu. Case Rep Oncol. 2010;3:268–271. doi: 10.1159/000319020. PubMed DOI PMC

Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005;115:1765–1776. doi: 10.1172/JCI24543. PubMed DOI PMC

Fortier AM, Asselin E, Cadrin M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem. 2013;288:11555–11571. doi: 10.1074/jbc.M112.428920. PubMed DOI PMC

Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009;2:34. doi: 10.1186/1755-8794-2-34. PubMed DOI PMC

Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer. 2013;13:268. doi: 10.1186/1471-2407-13-268. PubMed DOI PMC

Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009;454:647–656. doi: 10.1007/s00428-009-0770-6. PubMed DOI

Qian X, Anzovino A, Kim S, Suyama K, Yao J, Hulit J, Agiostratidou G, Chandiramani N, McDaid HM, Nagi C, et al. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene. 2014;33:3411–3421. doi: 10.1038/onc.2013.310. PubMed DOI PMC

ElMoneim HM, Zaghloul NM. Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: An immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt. Clinics (Sao Paulo) 2011;66:1765–1771. PubMed PMC

Shang X, Lin X, Manorek G, Howell SB. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol. 2013;83:85–94. doi: 10.1124/mol.112.079798. PubMed DOI

Kulka J, Szász AM, Németh Z, Madaras L, Schaff Z, Molnár IA, Tokés AM. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol Oncol Res. 2009;15:59–64. doi: 10.1007/s12253-008-9089-x. PubMed DOI

Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum Pathol. 2004;35:1531–1536. doi: 10.1016/j.humpath.2004.09.015. PubMed DOI

Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F. Claudin-low breast cancers: Clinical, pathological, molecular and prognostic characterization. Mol Cancer. 2014;13:228. doi: 10.1186/1476-4598-13-228. PubMed DOI PMC

Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011;3:227–233. doi: 10.4297/najms.2011.3227. PubMed DOI PMC

Wang W, Wang L, Mizokami A, Shi J, Zou C, Dai J, Keller ET, Lu Y, Zhang J. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chin J Cancer. 2017;36:35. doi: 10.1186/s40880-017-0203-x. PubMed DOI PMC

Nakamura T, Kato Y, Fuji H, Horiuchi T, Chiba Y, Tanaka K. E-cadherin-dependent intercellular adhesion enhances chemoresistance. Int J Mol Med. 2003;12:693–700. PubMed